Biogen (BIIB) and Stoke Therapeutics just published final results from the two-year BUTTERFLY study. The data highlights that neurodevelopment in Dravet syndrome patients plateaus at around age two, ...

ACI Worldwide , a global leader in real-time payments software serving thousands of financial institutions and merchants worldwide, will participate in three major investor conferences where ...

Booz Allen Hamilton and Comstock Companies announced today Booz Allen will relocate its global headquarters from McLean, Va. to Reston, Va. The company will occupy a newly constructed facility in The ...

Despite treatment with standard-of-care anti-seizure medicines, children with Dravet syndrome experienced high seizure burden and plateaued in neurodevelopment, resulting in a widening gap relative to ...

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the ...

Despite treatment with standard-of-care anti-seizure medicines, children with Dravet syndrome experienced high seizure burden ...

Stoke has a strategic collaboration with Biogen to develop and commercialize zorevunersen for Dravet syndrome. Under the collaboration, Stoke retains exclusive rights for zorevunersen in the United ...

Dravet syndrome occurs globally and is not concentrated in a particular geographic area or ethnic group. Currently, it is estimated that up to 38,000 people are living with Dravet syndrome in the U.S.

– An analysis designed to evaluate the potential effects of the Phase 3 zorevunersen dosing regimen showed continuing improvements in cognition and behavior at 2 years; results contrast with minimal ...

Hosted in honor of Anna Odlaug, this year's event raised a record-breaking amount! We are overwhelmed with gratitude for the generosity of St Louis - setting a record with over $900,000 raised this ...